Easterly Investment Partners LLC Sells 28,833 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Easterly Investment Partners LLC lowered its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 21.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 105,651 shares of the company's stock after selling 28,833 shares during the period. Easterly Investment Partners LLC owned 0.23% of Pacira BioSciences worth $1,990,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Caitlin John LLC boosted its stake in shares of Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock worth $35,000 after acquiring an additional 1,776 shares during the period. Nisa Investment Advisors LLC lifted its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock valued at $62,000 after purchasing an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Pacira BioSciences by 16.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock worth $68,000 after purchasing an additional 513 shares during the period. Virtus Investment Advisers Inc. acquired a new position in shares of Pacira BioSciences in the third quarter valued at $98,000. Finally, Quest Partners LLC raised its position in shares of Pacira BioSciences by 137.6% in the third quarter. Quest Partners LLC now owns 9,410 shares of the company's stock valued at $142,000 after purchasing an additional 5,449 shares during the period. Institutional investors own 99.73% of the company's stock.

Remove Ads

Analyst Ratings Changes

Several analysts recently commented on PCRX shares. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Barclays boosted their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Truist Financial upgraded Pacira BioSciences from a "sell" rating to a "hold" rating and increased their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, HC Wainwright lifted their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a "buy" rating in a report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $27.22.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX traded down $0.30 during trading on Monday, reaching $24.62. 103,362 shares of the company traded hands, compared to its average volume of 933,977. The firm has a market capitalization of $1.14 billion, a PE ratio of -12.14 and a beta of 0.86. Pacira BioSciences, Inc. has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The company's 50 day moving average is $24.76 and its two-hundred day moving average is $20.00.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.